Igor Bondarenko
Igor Bondarenko
Professor of Oncology, Dnipropetrovsk Medical Academy (Ukraine)
Підтверджена електронна адреса в dsma.dp.ua
Назва
Посилання
Посилання
Рік
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
C Robert, L Thomas, I Bondarenko, S O'Day, J Weber, C Garbe, C Lebbe, ...
New England Journal of Medicine 364 (26), 2517-2526, 2011
41892011
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, ...
Journal of clinical oncology 27 (5), 663-671, 2009
18902009
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative …
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
The lancet oncology 16 (1), 25-35, 2015
13112015
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
12672014
Risk of natalizumab-associated progressive multifocal leukoencephalopathy
G Bloomgren, S Richman, C Hotermans, M Subramanyam, S Goelz, ...
New England Journal of Medicine 366 (20), 1870-1880, 2012
11032012
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind …
TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, ...
Journal of clinical oncology 30 (17), 2046-2054, 2012
9532012
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor …
NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, ...
Journal of clinical oncology 29 (10), 1252-1260, 2011
9322011
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
9292015
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous …
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ...
The Lancet Oncology 17 (4), 425-439, 2016
8132016
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C Bokemeyer, I Bondarenko, JT Hartmann, F De Braud, G Schuch, ...
Annals of oncology 22 (7), 1535-1546, 2011
7842011
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised …
M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, ...
The lancet oncology 15 (2), 143-155, 2014
7242014
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ...
J Clin Oncol 28 (30), 4594-4600, 2010
5992010
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung …
MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, ...
J Clin Oncol 30 (17), 2055-2062, 2012
5852012
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ...
New England Journal of Medicine 380 (12), 1116-1127, 2019
5182019
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
SJ O'day, M Maio, V Chiarion-Sileni, TF Gajewski, H Pehamberger, ...
Annals of Oncology 21 (8), 1712-1717, 2010
5062010
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind …
M Reck, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, ...
Annals of Oncology 24 (1), 75-83, 2013
5012013
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial
RJ Motzer, D Nosov, T Eisen, I Bondarenko, V Lesovoy, O Lipatov, ...
Journal of clinical oncology 31 (30), 3791, 2013
411*2013
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ...
The Lancet 393 (10183), 1819-1830, 2019
4042019
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial
M Maio, JJ Grob, S Aamdal, I Bondarenko, C Robert, L Thomas, C Garbe, ...
Journal of clinical oncology 33 (10), 1191, 2015
3902015
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
C Bokemeyer, I Bondarenko, JT Hartmann, FG De Braud, C Volovat, ...
Journal of Clinical Oncology 26 (15_suppl), 4000-4000, 2008
3712008
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20